← Back to Clinical Trials
Recruiting NCT06389344

NCT06389344 Effect of Esketamine on Conscious State in Patients With pDoC

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06389344
Status Recruiting
Phase
Sponsor Beijing Tiantan Hospital
Condition Esketamine
Study Type INTERVENTIONAL
Enrollment 116 participants
Start Date 2024-05-20
Primary Completion 2025-12-31

Trial Parameters

Condition Esketamine
Sponsor Beijing Tiantan Hospital
Study Type INTERVENTIONAL
Phase N/A
Enrollment 116
Sex ALL
Min Age 16 Years
Max Age 65 Years
Start Date 2024-05-20
Completion 2025-12-31
Interventions
Esketaminenormal saline

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The goal of this clinical trial is to learn about the effect of intraoperative infusion of subanesthetic dose of esketamine on conscious status in patients with prolonged disorders of consciousness under sevoflurane anesthesia. Participants will be patients with prolonged disorders of consciousness undergoing surgery with general anesthesia at Beijing Tiantan Hospital. 0.3mg/kg esketamine or saline will be infused will be infused intravenously at a constant speed within 30 min after tracheal intubation/pneumatectomy fixation. Coma recovery scale-revised, Glasgow coma scale, Full Outline of UnResponsiveness scores, SedLine multi-channel electroencephalogram and perioperative adverse events after surgery will be investigated.

Eligibility Criteria

Inclusion Criteria: 1.16-65 years old 2.Native Chinese language 3.pDoC after acquired brain injury 4.Scheduled to undergo surgery 5.Signed informed consent Exclusion Criteria: 1. Continuous sedation treatment was carried out within 72 hours before the study 2. Airway stenosis and severe ventilation or ventilation dysfunction caused by various reasons 3. Known or suspected to have serious cardiac, pulmonary and renal dysfunction 1)Severe cardiac dysfunction: a. unstable coronary syndrome b. Congestive heart failure: left ventricular ejection fraction less than 50%, elevated BNP c.Severe arrhythmia d. History of severe valvular disease 2)Severe pulmonary dysfunction: a. history of pulmonary heart disease b. History of chronic obstructive pulmonary disease 3)Severe renal dysfunction: a. Endogenous creatinine clearance (Ccr) less than 30ml/min b. The glomerular filtration rate (GFR) was less than 30ml/min•1.73m2 4. Allergic history of sedative drugs 5. Combined with other mental or nervous

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology